Home » Newsletters » BioWorld Science

BioWorld Science

June 18, 2018

View Archived Issues

Mutation links bipolar disorder to mitochondrial dysfunction

Teva discontinues two studies in phase III ENFORCE clinical development program of fremanezumab

Optimized benzothiazole amides presented as potential novel class of antimycobacterial agents

Blueprint Medicines reports updated data from ongoing phase I EXPLORER study of avapritinib

AGEN-2034 demonstrates early signs of clinical activity in cervical and ovarian tumors

URAT1 inhibitors identified at Atom Bioscience and Pharmaceutical

Integrative Research Laboratories Sweden describes modulators of neurotransmission

Jiangsu Hengrui Medicine, Shanghai Hengrui Pharmaceutical patent TLR7 agonists

CV6 Therapeutics identifies dUTPase inhibitors

Teijin Pharma divulges cyclin-dependent kinase CDK4/cyclin D3 and CDK6/cyclin D3 inhibitors

BridgeBio licenses LHON therapy from NeuroVive

hVIVO reports results from phase IIb field study of FLU-v

CytomX initiates first-in-human study of CX-2029 in patients with solid tumors or DLBCL

Phase I/II study of BioAtla's BA-3021 in advanced solid tumors begins

STF-1019 protects against experimental enterovirus 71 infection

Stemline Therapeutics presents data on SL-401 potentially useful in systemic sclerosis

Nirogacestat receives U.S. orphan drug designation for desmoid tumors

Celltrion resubmits aBLA for trastuzumab biosimilar CT-P6

Aminex initiates phase I study of AMXT-1501 dicaprate in advanced solid tumors

Evotec and Sanofi sign agreement in infectious diseases

Idorsia starts phase III REACT study with clazosentan

Phase Ib/IIa data for a small-molecule BET inhibitor PLX-51107

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 16, 2026.
Precision psychiatry beyond, or before, biomarkers
BioWorld
There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...
Keros reports beneficial effects of RKER-065 in ALS model
BioWorld Science
Keros Therapeutics Inc. has presented data regarding their activin receptor ligand trap, RKER-065, for the inhibition of the activin/myostatin signaling axis.
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
First-in-class POLG activator restores mtDNA across mutations
BioWorld Science
Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...